CMPS 📈 Compass Pathways - Overview
Exchange: NASDAQ • Country: United Kingdom • Currency: USD • Type: Common Stock • ISIN: US20451W1018
CMPS: Psilocybin, Therapy, Treatment
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom. Web URL: https://compasspathways.com
Additional Sources for CMPS Stock
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
CMPS Stock Overview
| Market Cap in USD | 296m |
| Sector | Healthcare |
| Industry | Medical Care Facilities |
| GiC Sub-Industry | Health Care Services |
| IPO / Inception | 2020-09-18 |
CMPS Stock Ratings
| Growth 5y | -94.0% |
| Fundamental | - |
| Dividend | - |
| Rel. Strength Industry | -1019 |
| Analysts | 4.6/5 |
| Fair Price Momentum | 2.41 USD |
| Fair Price DCF | - |
CMPS Dividends
No Dividends PaidCMPS Growth Ratios
| Growth Correlation 3m | -87.6% |
| Growth Correlation 12m | -90.1% |
| Growth Correlation 5y | -90.7% |
| CAGR 5y | -37.22% |
| CAGR/Mean DD 5y | -0.54 |
| Sharpe Ratio 12m | -0.81 |
| Alpha | -91.25 |
| Beta | 1.50 |
| Volatility | 76.02% |
| Current Volume | 1170.4k |
| Average Volume 20d | 705.9k |
What is the price of CMPS stocks?
As of December 22, 2024, the stock is trading at USD 3.97 with a total of 1,170,381 shares traded.
Over the past week, the price has changed by -5.92%, over one month by -14.81%, over three months by -45.24% and over the past year by -47.28%.
As of December 22, 2024, the stock is trading at USD 3.97 with a total of 1,170,381 shares traded.
Over the past week, the price has changed by -5.92%, over one month by -14.81%, over three months by -45.24% and over the past year by -47.28%.
Is Compass Pathways a good stock to buy?
No, based on ValueRay Analyses, Compass Pathways (NASDAQ:CMPS) is currently (December 2024) a stock to sell. It has a ValueRay Growth Rating of -94.04 and therefor a clear technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CMPS as of December 2024 is 2.41. This means that CMPS is currently overvalued and has a potential downside of -39.29%.
No, based on ValueRay Analyses, Compass Pathways (NASDAQ:CMPS) is currently (December 2024) a stock to sell. It has a ValueRay Growth Rating of -94.04 and therefor a clear technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of CMPS as of December 2024 is 2.41. This means that CMPS is currently overvalued and has a potential downside of -39.29%.
Is CMPS a buy, sell or hold?
Compass Pathways has received a consensus analysts rating of 4.60. Therefor, it is recommend to buy CMPS.
Compass Pathways has received a consensus analysts rating of 4.60. Therefor, it is recommend to buy CMPS.
- Strong Buy: 6
- Buy: 4
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecast for CMPS stock price target?
According to ValueRays Forecast Model, CMPS Compass Pathways will be worth about 2.7 in December 2025. The stock is currently trading at 3.97. This means that the stock has a potential downside of -31.49%.
According to ValueRays Forecast Model, CMPS Compass Pathways will be worth about 2.7 in December 2025. The stock is currently trading at 3.97. This means that the stock has a potential downside of -31.49%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 21.2 | 434.5% |
| Analysts Target Price | 41.7 | 949.6% |
| ValueRay Target Price | 2.7 | -31.5% |